SerpinF2-Binding Molecules for Ischemic Stroke Neuroprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ischemic stroke, such as tissue plasminogen activator (TPA), often result in neurotoxic effects, increased risk of brain hemorrhage, and limited disability reduction, as they do not effectively address thrombotic occlusions, which are the primary cause of human ischemic strokes.
Innovation Solution
Administering a SerpinF2-binding molecule, such as an antibody, peptide, or small molecule, to reduce SerpinF2 activity or concentration, thereby inhibiting hemorrhage, organ edema, and apoptosis caused by TPA toxicity and prolonged ischemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If tissue plasminogen activator (TPA) is administered to treat ischemic stroke, then thrombotic occlusion is dissolved and blood flow is restored, but neurotoxic effects are caused and brain hemorrhage risk increases
Solution Approach 1:
The patent introduces SerpinF2-binding molecules as intermediary agents that modulate the TPA-plasmin-SerpinF2 interaction. These molecules bind to SerpinF2 and prevent it from inhibiting plasmin, thereby enhancing TPA's thrombus-dissolving effect while reducing the harmful feedback inhibition that contributes to neurotoxicity and hemorrhage risk.
Solution Approach 2:
The patent changes the concentration and activity parameters of SerpinF2 in the treatment system. By administering SerpinF2-binding molecules that reduce SerpinF2 levels or activity, the patent optimizes the plasmin generation from TPA, achieving better thrombus dissolution with reduced harmful effects on neural tissue and vascular integrity.
2Reliability
If SerpinF2 activity is maintained to protect against TPA-induced neurotoxicity, then neuronal cell death is reduced, but thrombotic occlusion dissolution is impaired
Solution Approach 1:
The patent creates a dynamic treatment approach where SerpinF2 activity is temporarily modulated during the acute phase to enhance thrombus dissolution, then restored for neuroprotection. The SerpinF2-binding molecules provide time-dependent control, allowing plasmin activity to peak when needed for clot dissolution while preventing excessive neurotoxic effects.
Solution Approach 2:
The treatment employs periodic modulation of the plasminogen activation system. SerpinF2-binding molecules are administered to create periods of enhanced plasmin activity for thrombus dissolution, followed by periods where endogenous SerpinF2 provides neuroprotection, achieving both therapeutic goals through temporal separation of functions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The SerpinF2-binding molecule significantly reduces neuronal cell death, brain swelling, hemorrhage, and disability by preventing breakdown of the blood-brain barrier and apoptosis, thereby improving survival and functional outcomes in ischemic stroke patients.
Implementation Method 1
administering a SerpinF2-binding molecule, such as an antibody, peptide, or small molecule, to reduce SerpinF2 activity or concentration
Data Source
AI summary
Compositions and methods of using SerpinF2-binding molecules for preventing and/or reducing organ damage, functional disability or mortality in a patient at risk due to the activity of SerpinF2 and/or plasminogen activators on tissue injury. Also provided are compositions and methods of using SerpinF2-binding molecules for inhibiting hemorrhage, edema, and apoptosis. Methods for the preparation of medicaments for such methods of treatment and prevention are provided.